ID 原文 译文
917 病毒滴度测定：将病毒原液按10倍系列稀释后，采用微量细胞病变法测定TCID50，或采用蚀斑试验计数蚀斑形成单位（plaque forming unit，PFU）测定病毒感染活力。 Virus titer measurement: After diluting the virus stock concentration by a factor of 10 in series, the TCID50 is determined by the micro-cytopathic method. Otherwise, viral viability is determined by plaque forming unit (PFU).
918 血清抗体检测 Detection of Serum Antibody
919 SARS-CoV-2感染后会产生特异性抗体。 Specific antibodies are produced after SARS-CoV-2 infection.
920 血清抗体测定方法有：胶体金免疫层析法、ELISA、化学发光免疫分析等。患者血清特异性IgM阳性，或恢复期特异性IgG抗体滴度较急性期升高4倍及以上，可作为核酸检测阴性疑似患者的诊断依据。 Serum antibody determination methods include colloidal gold immunochromatography, ELISA, chemiluminescence immunoassay, etc. Positive serum-specific IgM, or specific IgG antibody titer in the recover y phase ≥4 times higher than that in the acute phase, can be used as diagnostic criteria for suspected patients with negative nucleic acid detection.
921 通过随访监测，发现在患者发病后10天可检出IgM，发病后12天检出IgG，并随着血清抗体水平升高，病毒核酸载量逐渐下降。 During follow-up monitoring, IgM is detectable 10 days after symptom onset and IgG is detectable 12 days after symptom onset. The viral load gradually decreases with the increase of serum antibody levels.
922 炎症反应指标的检测 Detecting Indicators of Inflammatory Response
923 建议开展C反应蛋白、降钙素原、铁蛋白、D-二聚体、淋巴细胞总数及亚群、IL-4、IL-6、IL-10、TNF-α、INF-γ等反应机体炎症与免疫状态的检查，有助于判断临床进程，预警重症、危重症倾向，并为治疗策略制订提供依据。 It is recommended to conduct test s of C-reactive protein, procalcitonin, ferritin, D-dimer, total and subpopulations of lymphocytes, IL-4, IL-6, IL-10, TNF-α, INF-γ and other indicators of inflammation and immune status, which can help evaluate clinical progress, alert severe and critical tendencies, and provide a basis for the formulation of treatment strategies.
924 大多数新冠肺炎患者降钙素原正常，C反应蛋白显著升高，C反应蛋白迅速大幅升高提示可能出现继发感染。 Most patients with COVID-19 have a normal level of procalcitonin with significantly increased level s of C-reactive protein. A rapid and significantly elevated C-reactive protein level indicates a possibility of secondary infection.
925 重症患者D-二聚体水平显著升高，是患者预后不良的潜在危险因素。 D-dimer level s are significantly elevated in severe cases, which is a potential risk factor for poor prognosis.
926 发病初期淋巴细胞总数较低的患者一般预后较差，且重症患者外周血淋巴细胞数量呈进行性减少。 Patients with a low total number of lymphocytes at the beginning of the disease generally have a poor prognosis. Severe patients have a progressively decreased number of peripheral blood lymphocytes.